The FY2025 (Dec) proxy of Voyager Therapeutics names 18 peer companies for pay. Among Voyager Therapeutics and these peers, CEO pay was 4th highest of 6 and total shareholder return was 4th highest of 6.
4th highest of 6in Voyager Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$2.1M$8.3M
4th highest of 6in Voyager Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$23$202
Pay peer group, FY2025 (Dec) proxy
| MeiraGTx Holdings | ||
| Solid Biosciences | ||
| Neurogene | ||
| Editas Medicine | ||
| 4D Molecular Therapeutics | ||
| Adverum Biotechnologies, Inc. | Not disclosed | Not disclosed |
| Entrada Therapeutics | Not disclosed | Not disclosed |
| Foghorn Therapeutics | Not disclosed | Not disclosed |
| Lexeo Therapeutics | Not disclosed | Not disclosed |
| Monte Rosa Therapeutics | Not disclosed | Not disclosed |
| PepGen, Inc. | Not disclosed | Not disclosed |
| Prelude Therapeutics Inc. | Not disclosed | Not disclosed |
| Prime Medicine | Not disclosed | Not disclosed |
| Stoke Therapeutics | Not disclosed | Not disclosed |
| Tenaya Therapeutics, Inc. | Not disclosed | Not disclosed |
| Verve Therapeutics, Inc. | Not disclosed | Not disclosed |
| Vigil Neuroscience, Inc. | Not disclosed | Not disclosed |
| Wave Life Sciences | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.